Articles by Jill Wechsler - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jill Wechsler

Health Reform Challenges Biotech Industry

Pressures to reduce healthcare spending generates proposals to spur competition, cut costs.
Aug 1, 2009

Pressures to reduce healthcare spending generates proposals to spur competition, cut costs.

Extended Risk Management Proposals Challenge Manufacturers

The FDA seeks new strategies for improving the safe use of opioids and other high-risk medicines, including erythropoiesis stimulating agents.
Jul 1, 2009

The FDA seeks new strategies for improving the safe use of opioids and other high-risk medicines, including erythropoiesis stimulating agents.

Stiffer Enforcement at the FDA

Agency officials promise swift action against violators of drug safety and quality regulations.
Jun 1, 2009

Agency officials promise swift action against violators of drug safety and quality regulations.

Comparative Effectiveness Research to Shape Biotech Studies

Authorities are pushing for CE; manufacturers prefer to focus on value.
May 1, 2009

Authorities are pushing for CE; manufacturers prefer to focus on value.

Food and Drug Safety Crises Prompt White House, Congressional Action

The FDA is poised to gain more authority and resources to ensure product quality.
Apr 1, 2009

The FDA is poised to gain more authority and resources to ensure product quality.

Biotech Therapies Face Disclosure Requirements

Broader transparency in product prices and payments to researchers aim to curb conflicts of interest and rationalize drug expenditures.
Mar 1, 2009

Broader transparency in product prices and payments to researchers aim to curb conflicts of interest and rationalize drug expenditures.

Congress Approves Down Payment on Health Reform

Feb 27, 2009

In addition to providing tax breaks and investing billions to jump start the economy, last month?s economic stimulus package supports healthcare for the unemployed and takes steps to modernize the nation?s troubled healthcare system.

Biotech Drug Prices Under Scrutiny

Efforts to cut spending on healthcare will focus on outlays for prescription drugs by Medicare and other health programs.
Feb 1, 2009

With cuts in healthcare, biotech drugs are under scrutiny.

Revitalization, Reform Ahead for The FDA

FDA aims to regain public confidence in 2009.
Jan 1, 2009

FDA aims to regain public confidence in 2009.

ADVERTISEMENT

ADVERTISEMENT

Click here